Month: June 2026

Introduction and Objective: Abnormal angiogenesis is the leading cause of vision loss globally, but current anti-angiogenic treatments are unsatisfactory and incompetent. Thus, novel therapies targeting angiogenesis are urgently needed. Previously, we revealed a positive association between cGAS-STING signaling and angiogenic factors in the mouse model with ischemic retinopathy. However, whether cGAS-STING signaling regulates retinal angiogenesis […]

Introduction and Objective: RAY1225, a bi-weekly GLP-1/GIP receptor agonist, has demonstrated substantial potential for glycemic control and weight loss in phase 1 study. This phase 2 trial assessed the efficacy and safety of RAY1225 compared with placebo in Chinese overweight or obese adults without diabetes.Methods: In this multicenter, randomized, double-blind, placebo-controlled phase 2 trial, nondiabetic […]

Introduction and Objective: Early diabetic retinopathy (DR) is associated with inflammation and retinal neurodegeneration, which begin prior to overt microvascular pathology. Cannabinoid (CB) receptor 2 agonism has been shown to have anti-inflammatory and neuroprotective properties in the central nervous system. This study tested the potential of CB2-selective agonists HU-308 and CB65 to reduce inflammation and […]

Introduction and Objective: Data are limited as to whether continuous glucose monitoring (CGM) can be used to accurately diagnose gestational diabetes mellitus (GDM). We aimed to develop GDM diagnostic criteria based on CGM metrics at 24-28 weeks’ gestation.Methods: Planned analysis of a longitudinal, multi-site prospective cohort of gravidas without pregestational diabetes who wore a blinded […]

Introduction and Objective: AT7687 is a first-in-class peptide GIPR antagonist validated as anti-obesity therapy in obese monkeys, as monotherapy and in combination with liraglutide and cagrilintide. This randomized, double-blind, placebo-controlled study evaluated the safety, pharmacokinetics (PK), and pharmacodynamics of AT7687 (AT).Methods: In the single ascending dose (SAD) part, 60 participants randomized 6:2 by cohort received […]

Introduction and Objective: We tested the hypothesis that tirzepatide (TZ), a dual GLP-1/GIP agonist, improves metabolic health independent of weight loss via GIP effects on adipose cells. Dual GLP-1/GIP agonists are known to lower blood glucose to a greater degree than selective GLP-1 agonists. We quantified insulin resistance (IR) and adipose cell function after 6 […]

Introduction and Objective: Early type 1 diabetes (T1D) detection is vital to prevent DKA, which affects 60% of pediatric cases. However, traditional screening relies on invasive blood draws, limiting accessibility for young children. We launched the first “fully remote” T1D screening program designed for large-scale implementation using a novel genetic stratification tool alongside online monitoring […]

Introduction and Objective: Food Is Medicine interventions are being promoted to improve glycemic control in type 2 diabetes mellitus (T2D), but limited randomized trial (RCT) data exist. We evaluated the efficacy of a scalable, technology-based grocery prescription program in low-income, high-risk adults with T2D.Methods: We conducted a 1:1 RCT in Kaiser Permanente Northern & Southern […]

Introduction and Objective: Food insecurity leads to worse type 2 diabetes (T2D) outcomes, but which food insecurity intervention best improves T2D outcomes is unclear. Our objective was to compare the effectiveness of two food insecurity interventions: medically tailored meals (MTM) and food subsidies.Methods: Randomized comparative effectiveness trial (NCT04828785). Adults with T2D and food insecurity received […]